One study of paired pediatric HGGs found a trend toward increased number of mutations at recurrence in patients treated with temozolomide [ 51 ], but this did not reach statistical significance, and corresponding data in pediatric LGGs is lacking.
← all excerpts
Characterizing temporal genomic heterogeneity in pediatric low-grade gliomas.
1
—
—